Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations

AIDS Research and Human Retroviruses

Volumn 26, Issue 12, 2010, Pages 1267-1271

  Alencar, Cecília S ^a   Nishiya, Anna S ^b   Ferreira, Suzete ^b   Giret, Maria Teresa M ^c   Diaz, Ricardo S ^a   Sabino, Ester C ^b,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA; ENFUVIRTIDE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MARAVIROC; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BRAZIL; DNA POLYMORPHISM; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENVELOPE GENE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; PROVIRUS; VIRUS MUTATION; VIRUS STRAIN;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; BRAZIL; CYCLOHEXANES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PIPERAZINES; PREVALENCE; PROVIRUSES; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; TRIAZOLES;

EID: 78650266989     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0057     Document Type: Article

References (27)

1. Van Laethem K, Schrooten Y, Lemey P, et al.: A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 2005;123:25-34. (Pubitemid 39593730)
2. Wang T, Zhang Z, Wallace OB, et al.: Discovery of 4-benzoyl-1-[(4- methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236-4239.
3. Chinnadurai R, Rajan D, Munch J, Kirchhoff F: Human im-munodeficiency virus type 1 variants resistant to first-and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 2007;81:6563-6572.
4. Bar S, Alizon M: Role of the ectodomain of the gp41 trans-membrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol 2004;78:811-820.
5. Steffen I, Pohlmann S: Peptide-based inhibitors of the HIV envelope protein and other Class I viral fusion proteins. Curr Pharm Des 2010;16:1143-1158.
6. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR: Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004;78:4628-4637.
7. Menzo S, Castagna A, Monachetti A, et al.: Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004;48:3253-3259.
8. Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA: Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med Nov 13 2007;4:e305.
9. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
10. Hughes A, Nelson M: HIV entry: New insights and impli-cations for patient management. Curr Opin Infect Dis 2009;22:35-42.
11. Harrigan PR MR, Dong W, et al.: Screening for HIV tropism using population-based V3 genotypic analysis: A retro-spective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. XVIII International Drug Resistance Fort Myers, Florida.; 2009:June 9-13, 2009.
12. Guo Q, Ho HT, Dicker I, et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2003;77:10528-10536.
13. Madani N, Perdigoto AL, Srinivasan K, et al.: Localized changes in the gp120 envelope glycoprotein confer resis-tance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004;78:3742-3752.
14. Delwart EL, Shpaer EG, Louwagie J, et al.: Genetic relation-ships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
15. Carmona R, Perez-Alvarez L, Munoz M, et al.: Natural resistance- associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 ge-netic forms from T20 naive patients. J Clin Virol 2005;32:248-253.
16. Perez-Alvarez L, Carmona R, Ocampo A, et al.: Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006;78: 141-147.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16: 138-145.
18. Greenberg ML, Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54: 333-340.
19. Wei X, Decker JM, Liu H, et al.: Emergence of resistant hu-man immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
20. Lin PF, Blair W, Wang T, et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013-11018.
21. Westby M, Smith-Burchnell C, Mori J, et al.: Reduced max-imal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81: 2359-2371.
22. Sa-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, Morgado MG: Human immunodeficiency virus-1 sub-types and antiretroviral drug resistance profiles among drug-naive Brazilian blood donors. Transfusion 2007;47:97-102.
23. Oliveira AC, Martins AN, Pires AF, et al.: Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART. AIDS Res Hum Retroviruses 2009;25:193-198.
24. Teixeira C, de Sa-Filho D, Alkmim W, Janini LM, Diaz RS, Komninakis S: Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: Possible impact on enfuvirtide efficacy. AIDS Res Hum Retroviruses 2010;26:307-311.
25. Razzolini F, Vicenti I, Saladini F, et al.: Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses 2007;23:558-563.
26. Leung PH, Chen JH, Wong KH, et al.: High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong. J Clin Virol 2010; 47:273-275.
27. Diaz RS, Leal E, Sanabani S, et al.: Selective regimes and evolutionary rates of HIV-1 subtype B V3 variants in the Brazilian epidemic Virology 2008;381:184-193.